AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
06 January 2022 - 8:05AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on emerging immune control mechanisms applicable to
inflammation and immuno-oncology indications, today announced that
Hamza Suria, chief executive officer of AnaptysBio, will present an
overview of AnaptysBio as part of the 40th Annual J.P. Morgan
Healthcare Conference on Thursday, January 13, 2022 from 8:15 –
8:55 a.m. ET.
An audio webcast of the presentation will also be available via
https://jpmorgan.metameetings.net/events/healthcare22/sessions/40118-anaptysbio-inc/webcast?gpu_only=true&kiosk=true
or through the investor section of the AnaptysBio website at
https://ir.anaptysbio.com/events. A replay of the webcast will be
available for 30 days following the event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing
first-in-class antibody product candidates focused on unmet medical
needs in inflammation. The Company’s proprietary anti-inflammatory
pipeline includes imsidolimab, its anti-IL-36R antibody, previously
referred to as ANB019, for the treatment of dermatological
inflammatory diseases, including generalized pustular psoriasis, or
GPP, moderate-to-severe acne and moderate-to-severe hidradenitis
suppurativa; rosnilimab, its anti-PD-1 agonist program, previously
referred to as ANB030, for treatment of moderate-to-severe alopecia
areata; and its BTLA modulator program, ANB032, which is broadly
applicable to human inflammatory diseases associated with lymphoid
and myeloid immune cell dysregulation. AnaptysBio’s antibody
pipeline has been developed using its proprietary somatic
hypermutation, or SHM platform, which uses in vitro SHM for
antibody discovery and is designed to replicate key features of the
human immune system to overcome the limitations of competing
antibody discovery technologies. AnaptysBio has also developed
multiple therapeutic antibodies in an immuno-oncology collaboration
with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI
(dostarlimab-gxly) GSK4057190), an anti-TIM-3 antagonist antibody
(cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody
(GSK4074386), and an inflammation collaboration with Bristol-Myers
Squibb, including an anti-PD-1 checkpoint agonist antibody
(CC-90006) currently in clinical development.
Contact:Dennis MulroyAnaptysBio,
Inc.858.732.0201dmulroy@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2023 to Apr 2024